Predictive Oncology (NASDAQ:POAI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Predictive Oncology Inc. (NASDAQ:POAI)’s stock price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.95 and traded as low as $1.4431. Predictive Oncology shares last traded at $1.61, with a volume of 13,383 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Predictive Oncology to a “strong sell” rating in a research note on Saturday, December 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Predictive Oncology Stock Performance

The business’s fifty day moving average price is $2.81 and its 200-day moving average price is $6.95. The stock has a market cap of $5.46 million, a PE ratio of -0.12 and a beta of 1.35.

About Predictive Oncology

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.